Early antiretroviral treatment may preserve key immune responses to HIV
May 22, 2019
Ragon Institute study findings could pave the way to vaccine development CAMBRIDGE, Mass. – Instituting combination antiretroviral (ART) treatment at the earliest stages of HIV infection may allow the generation of functional CD8 “killer” T cells and preservation of the CD4 helper T cells that are the virus’s primary target. Investigators from the Ragon Institute […]